Back to Search
Start Over
Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.
- Source :
-
Journal of medical economics [J Med Econ] 2017 Dec; Vol. 20 (12), pp. 1224-1230. Date of Electronic Publication: 2017 Aug 22. - Publication Year :
- 2017
-
Abstract
- Background: Evidence of the cost-efficacy of ixekizumab for the treatment of moderate-to-severe plaque psoriasis (PsO) in the US is limited.<br />Objective: To estimate the number needed to treat (NNT) and monthly cost of achieving one additional Psoriasis Area and Severity Index (PASI) 75, 90, and 100 responder for ixekizumab and other Food and Drug Administration (FDA)-approved biologics in PsO.<br />Methods: A network meta-analysis estimated the probability of achieving PASI 75, 90, or 100 response during induction for each biologic. NNTs were calculated using response difference of each respective biologic vs placebo at the end of induction. Monthly costs per additional PASI responder were based on FDA-approved doses, wholesale acquisition costs, and induction NNTs.<br />Results: Induction NNTs for ixekizumab 80 mg once every 2 weeks (Q2W) relative to placebo were consistently lower across all levels of clearance compared with the other biologics. Monthly cost per additional responder was lowest for ustekinumab 45 mg at PASI 75 and for secukinumab 300 mg and ixekizumab 80 mg Q2W at PASI 90. Ixekizumab 80 mg Q2W had the lowest cost for PASI 100.<br />Conclusion: In this analysis, ixekizumab is the most cost-efficient biologic in the US when targeting complete resolution, as measured by PASI 100 in PsO.
- Subjects :
- Adalimumab economics
Adalimumab therapeutic use
Antibodies, Monoclonal economics
Antibodies, Monoclonal therapeutic use
Biological Products
Cost-Benefit Analysis
Etanercept economics
Etanercept therapeutic use
Humans
Network Meta-Analysis
Severity of Illness Index
Ustekinumab economics
Ustekinumab therapeutic use
Antibodies, Monoclonal, Humanized economics
Antibodies, Monoclonal, Humanized therapeutic use
Dermatologic Agents economics
Dermatologic Agents therapeutic use
Psoriasis drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1941-837X
- Volume :
- 20
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- Journal of medical economics
- Publication Type :
- Academic Journal
- Accession number :
- 28760056
- Full Text :
- https://doi.org/10.1080/13696998.2017.1362413